Dr Keqing Wang

  • Position: Associate Dean Research and Lecturer
  • Telephone: 0121 204 4060
  • Email:k.wang@aston.ac.uk
  • Room Number: MB314D 

Dr K Wang joined Aston University in 2012. She is a lecturer and Associate Dean for Research at Aston Medical School.

Dr Wang’s postdoctoral research was funded by European Research Council and Medical Research Council. She has extensive research experience in immunology, inflammation and the vascular biology of pregnancy. Her current research interests focus on the role of gaseous transmitters in the pathogenesis of preeclampsia, fetal growth restriction and cardiomyopathy. She discovered hydrogen sulphide (H2S) as an important regulator of the placental vasculature development and showed that a deficiency in its production causes preeclampsia-like features. This study identified H2S as a potential new target for therapeutic intervention against preeclampsia and fetal growth restriction. This work was highlighted as being a “groundbreaking study” by Circulation and within the media (see: Breakthrough in fight against pre-eclampsia).

  • 1998-2002: PhD inImmunology. University of Birmingham, UK.
  • 1997-1998: MSc in immunology. University of Birmingham, UK.
  • 1988-1993:  MD General Medicine. Tongji Medical School, Huazhong University of Science and Technology, China
  • 2016 – present  Lecturer/Associated Dean for Research/Lecturer of Aston Medical School, Aston University, UK.
  • 2013 – 2016    Aston Academic Research Fellow, Aston University, UK
  • 2012 –2013  MRC Postdoctoral Research Fellow, Aston University, UK.
  • 2010 – 2012 MRC Postdoctoral Research Fellow, University of Edinburgh, UK.
  • 2008 – 2010 MRC Postdoctoral Research Fellow, University of Birmingham, UK.
  • 2002 – 2008:   FP6 EU Postdoctoral Research Fellow, University of Birmingham, UK.
  • 2002:              Research Associate, University of Birmingham, UK.
  • 1993 – 1996:  Physician in Capital Pediatric Institution, Beijing, China.
  • Pathogenesis of preeclampsia - research from basic science to preclinical experimental disease models and paves way to development of novel therapies for preeclampsia.
  • Diagnosis of preeclampsia and fetal growth restriction. Identify novel biomarkers including gaseous molecules, microRNAs and metabolites markers, protein modifications and laser devices.
  • Development of treatment for preeclampsia and fetal growth restriction.
  • Vascular homeostasis and chronic inflammation.
  • Cardiomyopathy in pregnancy 
  • The relationship between inflammation and angiogenic imbalance in preeclampsia.
  • The roles of hydrogen sulphide producing enzymes in cardiomyopathy in pregnancy.
  • The roles of hydrogen sulphide in preeclampsia. 
  • 2015: BHF PhD studentship (2015) An investigation of the impact of soluble Flt-1 and soluble endoglin-induced sensitisation of the endothelium to pro-inflammatory cytokines to promote preeclampsia. Co-I with £107,160
  • 2018: European Union’s Horizon 2020 research and innovation programme ITN under the Marie Skłodowska-Curie: iPlacenta. Partner: £273,287.88
  • 2018: International PhD studentship : PI £72,000
  • 2018: Medtronic: £120,000. Co-I with Prof Francisco Leyva.
  • Pathogenesis of preeclampsia
  • Novel therapeutic targets for preeclampsia, fetal growth restriction
  • Vascular homeostasis and chronic inflammation
  • Cardiomyopathy in pregnancy 

Fujisawa T*, Wang K*, Niu X, Egginton S, Ahmad S, Hewett P, Kontos CD, A Ahmed. (2017) Angiopoietin-1 promotes atherosclerosis by increasing the proportion of circulating Gr1+ monocytes. Cardiovascular Research 113(1):81-89. doi: 10.1093/cvr/cvw223.


Cai M, Wang K, Murdoch CE, Gu Y, Ahmed A. (2017) Heterodimerisation between VEGFR-1 and VEGFR-2 and not the homodimers of VEGFR-1 inhibit VEGFR-2 activity. Vascul Pharmacol. 88:11-20. doi: 10.1016/j.vph.2016.11.007.


Ghosh CC, Thamm K, Berghelli AV, Schrimpf C, Maski MR, Abid T, Milam KE, Rajakumar A, Santel A, Kielstein JT, Ahmed A, Thickett D, Wang K, Chase M, Donnino MW, Aird WC, Haller H, David S, Parikh SM. (2015) Drug Repurposing Screen Identifies Foxo1-Dependent Angiopoietin-2 Regulation in Sepsis. Crit Care Med [Epub ahead of print]


Ahmad S, Hewett PH, Fujisawa T, Sissaoui S, Cai M, Gueron G, Al-Ani B, Cudmore M, Ahmed SF, Wong MMK, Wegiel B, Otterbein LE, Vítek L, Ramma W, Wang K, A. Ahmed. (2015) Carbon monoxide inhibits sprouting angiogenesis and vascular endothelial growth factor receptor-2 phosphorylation. Thromb Haemost 113 (2): 329-337.


Hampson P, Wang K, Ersvær E, McCormack E, Schüler K, Fiebig H-H, Gjertsen BT, Bruserud Ø, Lord JM. (2014) Up-regulation of anti-apoptotic genes confers resistance to the novel anti-leukaemic compound PEP005 in primary AML cells. Oncoscience 1(8): 529-539.


Wang K, Ahmad S, Cai M, Rennie J, Fujisawa T, Crispi F, Baily J, Miller MJ, Cudmore MJ, Hadoke PWF, Wang R, Gratacós E, Buhimschi IA, Buhimschi CS, and Ahmed A. (2014) Response to Letter Regarding Article, “Dysregulation of hydrogen sulfide (H2S) producing enzyme cystathionine γ-lyase (CSE) contributes to maternal hypertension and placental abnormalities in preeclampsia.” Circulation 129:e517-e518.


Wang K, Ahmad S, Cai M, Rennie J, Fujisawa T, Crispi F, Baily J, Miller MJ, Cudmore MJ, Hadoke PWF, Wang R, Gratacós E, Buhimschi IA, Buhimschi CS, and Ahmed A. (2013) Dysregulation of hydrogen sulfide (H2S) producing enzyme cystathionine γ-lyase (CSE) contributes to maternal hypertension and placental abnormalities in preeclampsia. Circulation 127:2514-2522.


Cudmore MJ, Hewett PW, Ahmad S, Wang KQ, Cai M, Al-Ani B, Fujisawa T, Sissaoui S, Ramma W, Miller M, Newby DE, Gu Y, Barleon B, Weich H and Ahmed A. (2012) Identification and functional characterisation of VEGF-A receptor heterodimerisation. Nat Comms 24;3:972. (PMID: 22828632).


Cudmore MJ, Ahmad S, Sissaoui S, Ramma W, Ma B, Fujisawa T, Al-Ani B, Wang K, Cai M, Crispi F, Hewett PW, Gratacós E, Egginton S, Ahmed A. (2012) Loss of Akt activity increases circulating soluble endoglin release in preeclampsia: identification of inter-dependency between Akt-1 and heme oxygenase-1. Eur Heart J. 33(9):1150-8.


Wang K, Hampson P, Hazeldine J, Krystof V, Strnad M, Pechan P, Lord JM. (2012) Cyclin-dependent kinase 9 activity regulates neutrophil spontaneous apoptosis. PLoS One7(1):e30128.


Sarkar A, Hellberg L, Bhattacharyya A, Behnen M, Wang K, Lord JM, Möller S, Kohler M, Solbach W, Laskay T. (2012)  Infection with Anaplasma phagocytophilum activates the phosphatidylinositol 3-Kinase/Akt and NF-κB survival pathways in neutrophil granulocytes. Infect Immun. Apr;80(4):1615-23.


Francis N, Wong SH, Hampson P, Wang K, Young SP, Deigner HP, Salmon M, Scheel-Toellner D, Lord JM. (2011) Lactoferrin inhibits neutrophil apoptosis via blockade of proximal apoptotic signaling events. Biochim Biophys Acta. 1813(10):1822-6.


Hampson P, Wang K, Milverton L, Ersvaer E, Bruserud O, Lord JM. (2010) Kinetics of ERK1/2 activation determine sensitivity of acute myeloid leukaemia cells to the induction of apoptosis by the novel small molecule ingenol 3-angelate (PEP005). Apoptosis 15(8):946-55.


Ahmad S, Cudmore MJ, Wang K, Hewett P, Potluri R, Fujisawa T, Ahmed A. (2010) Angiopoietin-1 induces migration of monocytes in a tie-2 and integrin-independent manner. Hypertension 56(3):477-83.


Radford DJ, Wang K*, McNelis JC. Taylor AE, Hechenberger G, Hofmann J, Chahal H, Arlt W, Lord JM. (2010) Dehdyroepiandrosterone sulfate directly activates protein kinase C-β to increase human neutrophil superoxide generation. Mol. Endocrinology. 24(4):813-21.


Hampson P, Kavanagh D, Smith E, Wang K, Lord JM, Ed Rainger G. (2008) The anti-tumor agent, ingenol-3-angelate (PEP005), promotes the recruitment of cytotoxic neutrophils by activation of vascular endothelial cells in a PKC-delta dependent manner. Cancer Immunol Immunother. 57(8):1241-51.